Erschienen in:
01.07.2020 | Concise Research Report
Novelty of Active Ingredients in High-Cost Brand-Name Drugs
verfasst von:
Emily H. Jung, A. B., Ameet Sarpatwari, J.D., Ph.D., Aaron S. Kesselheim, M.D., J.D., M.P.H.
Erschienen in:
Journal of General Internal Medicine
|
Ausgabe 7/2020
Einloggen, um Zugang zu erhalten
Excerpt
In 2017, prescription drugs accounted for about one-fifth of Medicare spending, with expenditures for the Part D outpatient drug insurance program totaling $94 billion.
1 In 2016, 84% of Part D spending came from brand-name drugs, which made up 14% of prescriptions overall.
2, 3 Since a common justification for the high prices of brand-name products is that they are needed to sustain new drug development, we examined the novelty of active ingredients in the 25 brand-name drugs with the highest Medicare Part D spending in 2017, which accounted for 30% of total Part D spending that year. …